ExploreWatchlistsPricing
  1. JP-listed companies
  2. kainos loboratories,inc
  3. Financials
  4. Cash and cash equivalents

kainos loboratories,inc (4556)

Market cap
¥10.4B
P/E ratio
16x
Kainos manufactures diagnostic pharmaceuticals, laboratory reagents, and medical devices for hospitals and research facilities to improve healthcare quality.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 20264,174+22.90%
Mar 31, 20253,396+7.01%
Mar 31, 20243,174+5.10%
Mar 31, 20233,020+12.82%
Mar 31, 20222,677+19.30%
Mar 31, 20212,244+14.23%
Mar 31, 20201,964+106.16%
Mar 31, 2019953-20.37%
Mar 31, 20181,196-0.45%
Mar 31, 20171,202+5.35%
Mar 31, 20161,141-15.29%
Mar 31, 20151,347

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat